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Abstract
The Bowman-Birk inhibitor (BBI) is a soybean-derived
serine protease inhibitor and a potential cancer
chemopreventive agent for humans. In this Phase I
clinical trial, BBI concentrate was administered as a
single oral dose to 24 subjects with oral leukoplakia.
Pharmacokinetics of BBI was analyzed, and subjects were
monitored clinically for toxic effects. Subjects received
between 25 and 800 chymotrypsin inhibitor units (CIU)
of the compound in a dose escalation trial. BBI was taken
up rapidly, and a metabolic product of BBI was excreted
in the urine within 24–48 h. No clinical or laboratory
evidence of toxicity was observed in the study. Protease
activity was also measured in buccal cells to evaluate
usefulness as a biomarker. Single-dose BBI concentrate
administered up to 800 CIU was well tolerated and
appeared to be nontoxic. Further investigation in Phase
II clinical trials is being done.
Introduction
The soybean-derived protease inhibitor known as the BBI3 is a
potent anticarcinogenic agent with activity demonstrated in a
variety of in vitro and in vivo carcinogenesis assay systems (1).
BBI was identified by Bowman in the 1940s (2) and purified by
Birk in 1961 (3). The protein contains 71 amino acids and has
two separate protease inhibitory sites, one each for trypsin and
chymotrypsin (4). The anticarcinogenic activity of BBI has
been localized to the chymotrypsin inhibitory region of the
protein molecule (5, 6), but the actual mechanism producing the
observed anticarcinogenic effects remains unknown (7). BBI is
resistant to digestive enzymes, and .90% of the BBI ingested
reaches the colon intact. BBI is taken up by epithelial cells of
the digestive tract, absorbed into the bloodstream, and distrib-
uted to all organs examined, except the brain (8, 9).
Interest in the use of soybean products as cancer-preven-
tive agents emanated from epidemiological studies demonstrat-
ing low incidence rates of several cancers in populations with
a high soy intake (10, 11). In Japan, which has a high dietary
intake of soy products, the incidence rates of several cancers
including breast, colon, and prostate cancer are very low (10,
12, 13). A number of compounds in soybeans have been stud-
ied, and several compounds, including phytic acid and b-sito-
sterol, have also demonstrated anticarcinogenic potential (11).
The anticarcinogenic activity of BBI has been detected at
nanomolar concentrations (5), and the ability of BBI to sup-
press carcinogenesis in animals far exceeds that of other po-
tential chemopreventive agents identified in soybeans (11).
Animal studies have shown that BBI is able to prevent the
development of malignancies in several different animal tumor
model systems (14–24). In vitro and animal studies using BBI
and BBIC are reviewed and summarized in several recent
publications (1, 7, 11, 22, 25, 26).
Soybeans are a major component of animal diets in the
United States and are a human dietary staple in certain parts of
the world. Early animal studies demonstrated growth inhibition
when animals were fed raw soybeans (27). This was errone-
ously attributed to protease inhibitors (1, 22). Pancreatic
changes are a potential toxicity concern because they have been
associated with trypsin inhibition in rats fed very high levels of
soybeans over long periods of time (28, 29). BBI contains some
trypsin inhibitory activity, but BBIC has greatly reduced trypsin
inhibitory activity compared with raw soybeans and many
soybean products (e.g., Refs.14–22 and 24). Adverse effects on
the pancreas have not been observed in animal studies using
BBIC including subchronic toxicity studies in rats and dogs.4
The current study was designed to determine whether oral
ingestion of BBIC produced any clinical or laboratory evidence
of toxicity. The trial design also evaluated the pharmacokinetics
of BBI and PA as a potential biomarker. Oral premalignancy
was selected as the initial clinical model to study BBIC in
humans because it provides an easily accessible site and has
well-defined premalignant lesions that can be monitored for
treatment effects. BBIC was administered as a single oral dose
to 24 subjects in a dose escalation trial in which clinical and
laboratory toxicity was monitored, and pharmacokinetic studies
(of BBI) were performed.
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Materials and Methods
Study Design
In this study, the effects of the administration of a single oral
dose of BBIC were monitored. The highest dose used in this
human trial was 800 CIU/day. This upper limit for human
dosing was established from the results of BBIC toxicity testing
in dogs. The highest dose of BBIC evaluated in dog toxicity
tests is 1000 mg/kg, which allowed United States Food and
Drug Administration approval for human trial doses of up to
800 CIU/day. Escalating doses were administered to subjects in
five doses (25, 100, 200, 400, and 800 CIU). A total of 24
subjects with oral leukoplakia were studied. Subjects under-
went oral examination to determine whether oral leukoplakia
was present, and blood was collected for clinical laboratory
assays (SMA-18 and CBC) to determine study eligibility. Each
subject received the study medication in a liquid suspension,
and subjects were observed for symptoms and signs of clinical
toxicity or drug allergy. Timed specimens were collected after
drug administration. Serum was obtained for pharmacokinetic
studies at 10, 15, 20, and 40 min; 1, 3, 6, 12, and 24 h; and 2
and 4 weeks. Urine samples were also obtained at 0, 1, 3, 6, 12,
24, and 48 h and at 2 and 4 weeks. Buccal cells were collected
by oral brushing before drug administration and at several
subsequent staggered occasions between 6 h and 4 weeks after
drug administration (6, 24, and 48 h and 2 and 4 weeks).
Approximately 4 weeks after drug administration, subjects
were interviewed by study personnel for symptoms of clinical
toxicity. Oral examination was repeated, and blood was ob-
tained for SMA-18 and CBC to evaluate for changes in labo-
ratory parameters.
Sample Collection and Specimen Handling
Serum for BBI measurements was separated by centrifugation
at 4°C and stored at 220°C until analyses were performed.
Urine samples were also stored at 220°C until analyses were
performed. Buccal cell samples were harvested by gently
brushing the oral mucosa with a soft toothbrush and rinsing the
mouth and toothbrush with PBS. The collected fluid was placed
on ice, filtered through cheesecloth, and centrifuged at 5000 3
g for 5 min at 4°C; the pellet was flash-frozen in liquid nitrogen
and stored at 270°C until analyzed. The timing of brushing
collections was spaced among the groups to allow reaccumu-
lation of surface cells.
Drug Formulation and Administration
BBIC produced and provided by Central Soya Company, Inc.
(Fort Wayne, IN) was prepared using methods described pre-
viously (30). Previously assayed BBIC powder containing ap-
proximately 100 CIU/g was dissolved in Roxane saliva substi-
tute (Roxane Laboratories, Columbus, OH) containing sorbitol,
carboxymethylcellulose, methylparaben, and water to yield a
troche. For the 25 and 100 CIU doses, 20 ml of solution were
made. At higher doses, the volume was increased up to 160
ml/dose so as not to exceed the solubility of BBIC. Doses were
administered to subjects as follows: (a) 25 CIU, six subjects;
(b) 100 CIU, six subjects; (c) 200 CIU, four subjects; (d) 400
CIU, five subjects; and (e) 800 CIU, three subjects. The doses
administered in this study expressed in terms of CIU are in the
range consumed in the Japanese diet, which contains a high
intake of soy products. For comparison, the average Japanese
dietary intake of soy products expressed in CIU is approxi-
mately 200 CIU/day, approximately four times that consumed
in the United States diet (25).
Eligibility/Exclusion Criteria
Persons at least 21 years of age with clinically observable oral
leukoplakia were eligible for enrollment. Females with child-
bearing potential were required to use an adequate method of
contraception. Postmenopausal females not taking conjugated
estrogen products were also eligible. Exclusion criteria were
pregnancy, unwillingness to protect against possible pregnancy,
allergy or adverse reaction (to soybeans or soybean products,
Roxane saliva substitute, sorbitol, carboxymethylcellulose, or
methylparaben), liver dysfunction (aspartate aminotrans-
ferase . 23 normal, alanine aminotransferase . 23 normal,
total bilirubin . 2.0 mg/dl), and renal disease (creatinine . 2.0
mg/dl). After determination of eligibility and explanation of the
study, all subjects signed a consent form approved by the
University of California, Irvine Institutional Review Board.
Analyses Performed
Measurement of BBI Levels. Timed serum and urine samples
were obtained for measurement of BBI content. We have pre-
viously produced and characterized several monoclonal anti-
bodies that react with reduced BBI as well as metabolized BBI
products in urine (31). One of the monoclonal antibodies,
designated 5G2, was used in this study to measure the BBI
concentrations in urine samples by an ELISA. In the early stage
of the study, a solid-phase ELISA method using filter mem-
brane-coated multiwell plates (Millipore) was used to detect
BBI in urine samples from patients who received a single dose
of 100, 200, or 400 CIU of BBIC. To measure BBI concentra-
tions by this method, urine samples were heated at 95°C for 10
min in the presence of 1% b-mercaptoethanol to reduce the
disulfides in the BBI molecules and then applied to Immo-
bilon-P filter membrane-coated multiwell plates at 100 ml/well
and incubated at room temperature for 1 h for the antigen to
attach. The liquid was removed from each well with a vacuum
manifold (Millipore) attached to the bottom of the plates, and
the plates were allowed to dry in air for 2 h. 5G2 antibody was
diluted 1:500 in 1% BSA in PB, applied to antigen-coated
multiwell plates in quadruplicate, and incubated at room tem-
perature for 1 h. Purified BBI (Sigma-Aldrich, St. Louis, MO)
was diluted in a control urine sample at various concentrations
and included in each run of the ELISA to generate a standard
curve. The plates were subsequently incubated for 1 h each with
b-galactosidase-conjugated secondary antibody (Southern Bio-
technology Associates, Birmingham, AL) and ONG substrate
(Sigma-Aldrich). The plates were washed three times with PB
between incubations. At the end of the incubation with the
ONG substrate, the plate was read with a plate reader at a
wavelength of 405 nm.
During the course of the studies, it was discovered that
some urine samples contained substances that interfered with
the BBI measurement by altering the hydrophobic characteris-
tics of the filter membrane in the multiwell plates. To overcome
this problem, an inhibitory ELISA method was developed and
used to measure BBI concentrations in urine samples collected
from patients who received a single dose of 400 or 800 CIU of
BBIC. To measure BBI concentrations by the inhibitory ELISA
method, 5G2 antibody was diluted 1:500 in 1% BSA and mixed
with each urine sample at equal volumes and incubated at room
temperature for 30 min. The antibody-urine mixtures were then
applied in triplicate at 100 ml/well to polystyrene 96-well plates
precoated with BBI that was reduced by a radiochemical
method in the presence of etanidazole as described previously
(31, 32). BBI-etanidazole was diluted in a control urine sample
at various concentrations and included in each run of the ELISA
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to generate a standard curve. The plates were incubated at room
temperature for 90 min. After washing three times with PB, the
plates were sequentially incubated with the b-galactosidase-
conjugated secondary antibody for 90 min and with the ONG
substrate solution for 1 h. At the end of the incubation with the
ONG substrate, the solution in each well was transferred to a
polystyrene 96-well plate and read with a plate reader at a
wavelength of 405 nm. To compensate for the fluctuations in
urine concentrations (water content), creatinine concentrations
in the urine samples were determined by using Fuller’s earth
method (33, 34), and the concentration of BBI was normalized
to the concentration of creatinine in each urine sample.
Measurement of PA. PA was analyzed using the synthetic
substrate Boc-Val-Pro-Arg-MCA (35, 36). Buccal cell pellets
were thawed on ice and homogenized in 600 ml of PBS.
Samples were analyzed using 50-ml aliquots of sample in 0.1 M
Tris (pH 7.5)-5 mM CaCl2 with the synthetic substrate. Samples
were incubated for 2 h at 37°C, and the reaction was terminated
by dilution with 1.8 ml of distilled H2O. Fluorescence from
released aminomethyl coumarin was determined spectrophoto-
metrically at excitation and emission wavelengths of 380 and
460 nm, respectively, in a Perkin-Elmer fluorescence spectro-
photometer. Protein content was determined by the Bradford
method (37), with BSA used as a standard. The spectrofluorom-
eter was standardized such that 1027 M aminomethyl couma-
rin 5 700 relative fluorescence units. Results were expressed as
relative fluorescence units/h/mg protein.
Statistical Analysis. Mean values before and after BBIC ad-
ministration were compared for serum and urine laboratory
values using the paired t test. For each patient, the blood and
serum CBC and SMA-18 test results were classified as normal
(within the laboratory reference range) or abnormal (outside the
laboratory reference range). McNemar’s statistical test (38) was
then used to examine whether or not the proportion of labora-
tory test values falling within or outside the reference range
remained the same after BBIC administration. For each statis-
tical test, the exact two-tailed P was computed. Pharmacoki-
netic data from the urine analyses were analyzed by first cal-
culating the percentage increase in urine BBIC concentration
from baseline for each sample. A Wilcoxon signed rank test
was performed to examine changes from baseline. Buccal cell
PA was analyzed similarly.
Results
Twenty-four subjects were enrolled in the study, consisting of
16 males and 8 females ranging in age from 48–73 years.
Median age was 57.5 years. Twenty Caucasians, two Hispanics,
one Asian, and one African American participated in the trial.
Administration of BBIC as a single-dose troche in doses rang-
ing from 25–800 CIU in a total of 24 subjects resulted in no
clinically observed toxicities. All subjects completed follow-up
visits to assess for clinical toxicity. No subjects reported ad-
verse effects after ingestion of BBIC. No allergic reactions,
gastrointestinal side effects, or constitutional symptoms were
elicited. There was no change in the leukoplakic oral lesions in
any of the subjects.
Blood (serum) was obtained before and approximately 4
weeks after BBIC administration. Complete pre- and post-
SMA-18 values were available for 21 of 24 subjects, and
complete pre- and post-CBC values were available for 14 of 24
subjects (incomplete data collection for CBC was due to a
systematic technical error in obtaining and handling specimens
during the collection process). The majority of laboratory val-
ues were within the reference range for each test. Mean test
values were calculated before and after drug administration and
compared with a two-tailed t test. Statistically significant (P ,
0.05) changes were observed for RBC, Hgb, total protein, and
globulin. Hct was also shown to have a nearly significant (P 5
0.06) change. RBC, Hgb, and Hct means all decreased slightly.
However, the absolute magnitude of the shifts in the means was
small, and all of the means were within the normal range for
each parameter. RBC count decreased from 4.79 to 4.63 million
cells/mcl, Hgb decreased from 15.28 to 14.81 g/dl, and Hct
decreased from 44.88% to 43.79%. Closer examination of
changes in the mean CBC values demonstrated that three sub-
jects accounted for most of the change. Two males had de-
creases in Hct of 24.5% and 23.1%, and one female had a
decrease in Hct of 22.6%. All three had starting Hcts over
40%, and the lowest Hct encountered in the study was 39%.
Mean total protein decreased from 7.35 to 7.08 g/dl, and glob-
ulin decreased from 3.08 to 2.83 g/dl. Mean lactate dehydro-
genase values were not calculated because approximately half
way through the study, the clinical laboratory changed instru-
mentation for this test, and the reference range decreased from
313–618 IU/liter to 91–180 IU/liter, rendering calculation of
the mean values of little use.
Serum data were also analyzed to determine the proportion
of values outside the normal reference range for each test.
Overall, the majority of laboratory values were normal both
before and after treatment. Of the subjects who had an abnormal
laboratory value, most were aberrant both before and after drug
administration (15 of 126 CBC values and 18 of 418 SMA-18
values). The proportion of values that normalized after drug
administration and the proportion of normal values that became
abnormal after drug administration were approximately equal.
Four of 126 abnormal CBC values were within the reference
range after BBIC, whereas 5 of 126 normal values became
abnormal. For serum SMA-18, 20 of 418 values normalized,
and 22 of 418 values became abnormal. The proportion of
normal and abnormal test values did not differ significantly
before and after BBIC administration [P . 0.12 for all labo-
ratory tests (McNemar’s test)].
Serum and Urine Pharmacokinetic Results. A solid-phase
ELISA method was used on the initial urine and serum samples
from the patients who received a dose of 100, 200, or 400 CIU
of BBIC. BBI was not detected in the serum samples tested
using this assay. Because of this finding, further serum BBI
assays were not performed in this trial. Using the initial solid-
phase ELISA method for the detection of BBI, identifiable
peaks in urine BBI were seen in 8 of 11 subjects, occurring
between 2 and 9 h after drug administration. The relative
percentage increase of BBI in those subjects exhibiting in-
creased urine BBI over baseline ranged from 5.9–118%. Urine
BBI levels, measured by modification of the initial protocol to
an inhibitory ELISA, demonstrated peak excretion 3–10 h after
drug administration in the four subjects studied with this im-
proved method. The range of peak percentage increase was
154–895% (findings are displayed in Table 1). There was not
enough urine remaining from the first 11 subjects to repeat the
assays using the improved methods.
PA. Changes in PA measured in buccal cells after BBIC in-
gestion were highly variable. There were marked changes in
levels of PA at 6 h for six of the seven subjects measured at this
time point, with a marked increase in PA for three patients (with
the levels increasing by 90.9 6 34.7%) and a marked decrease
in PA for three patients (with the levels being reduced by
55.3 6 51.1%). The mean PA values for each time period
analyzed are shown in Table 2. The number of samples ob-
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tained at each time interval was small because buccal cells were
not harvested from each subject at each time period. For each
individual patient, a sufficient time between buccal cell har-
vests had to occur to allow for epithelial cell maturation and
sloughing. There was a trend toward a slight increase in PA
after BBIC administration, but due to the wide variability in PA
response after BBIC administration, no statistically significant
change in mean PA from baseline was detected.
Discussion
BBIC was well tolerated when administered p.o. in this trial.
No toxic or allergic reactions were recorded during the study.
The doses administered ranged from levels near those obtained
in the Western diet (25 CIU) to approximately four times those
ingested in the Japanese diet (800 CIU).
Statistically significant decreases in mean RBC, Hgb, total
protein, and globulin were observed for the group as a whole.
The absolute magnitudes of the changes were small, and for
these tests, almost every laboratory value remained within the
normal range for the test, and all mean values were well within
the normal range for the test. The magnitude of changes in the
mean values, although statistically significant, is not biologi-
cally indicative of toxicity from BBIC. This is supported by
analysis of shifts in the proportion of values falling within or
outside the normal range after BBI administration. For each of
the four tests showing a statistically significant shift in the mean
values, McNemar’s test P was either 1.0 or was not calculable
because no values were outside the reference range for the test.
Further study with a larger sample size is planned to determine
whether these subtle observations of concern are due to BBI or
other factors or represent random findings.
Analysis of urine pharmacokinetic data for BBIC was
complicated by discovery in the early studies that the measure-
ment of BBI by the solid-phase ELISA using filter membrane-
coated multiwell plates can be compromised by the presence of
unidentified urine substances and by the great fluctuations in
the water content of the urine samples. To overcome these
problems, urinary BBI concentrations in the later studies were
determined by the inhibitory ELISA method and normalized to
the urinary concentration of creatinine. Urine samples from
four patients who received a single dose of 400 or 800 CIU of
BBIC were measured by this method (urine samples from other
patients were not measured by this method because the samples
were exhausted before this improved method was developed).
The results from both assays showed BBIC to be rapidly
excreted in the urine between 3 and 12 h after administration,
decreasing markedly by 48 h. This is consistent with observa-
tions made in animal pharmacokinetic studies that demonstrate
that approximately half of p.o. ingested BBI is taken up in the
bloodstream and distributed through the body and that BBI has
a serum half life of 10 h in rats and hamsters and is excreted in
both the urine and feces (1, 8, 9). Animal pharmacokinetic
studies of BBI have been summarized by Kennedy (1). The
origin of the late peak seen in one subject (subject 22) is unclear
and inconsistent with observations in animal studies but could
have resulted from consumption of food products containing
BBI in the diet.
PA in the buccal mucosal cells was highly variable in this
trial, with both increases and decreases in PA observed in the
patients. The mean values of Boc-Val-Pro-Arg-MCA hydro-
lyzing activity increased between 19% and 32% from baseline
at all time periods sampled for each dosage group, but the
responses were very variable as shown by the confidence in-
tervals, and the changes were not found to be statistically
significant. Several factors may account for the variable re-
sponse observed. First, the population studied was heterogene-
ous, and no control for diet was made. Significant ingestion of
products containing high levels of dietary protease inhibitors
before or during the study could alter the assay results and
camouflage the biological effects of BBI. Additionally, it is
possible that there is a differential response to BBI administra-
tion among different subjects. No control was made for smok-
ing status, which elevates PA (36). Histopathological analysis
of the oral lesions was not performed. It is possible that PA may
respond differently with severely dysplastic lesions than with
mildly hyperplastic lesions. Both sustained increases and de-
creases in PA were observed in several subjects after BBIC
administration, which could represent differential tissue re-
sponses to BBIC treatment.
Although no statistically significant changes or patterns of
change in PA were observed in this single-dose study, more
work needs to be completed to better characterize the effects of
BBIC on PA in exfoliated mucosal cells and to define its utility
as a potential intermediate marker end point. Animal data
Table 1 Urinary excretion of BBIa
Subject
no.
Dose
(CIU)
Baseline BBI
(ng/mg)
Time to peak
excretion (h)
Peak BBI
(ng/mg)
Increase
(ng/mg)
Percentage
increase
20 400 125 10 621 497 399
21 400 24.3 6 61.6 37.3 154
22 800 10.6 3 79 68.4 642
23 800 1.85 4 18.4 16.6 895
a BBI measurements were recorded as nanograms of BBI per milligram of creatinine using the inhibitory ELISA technique described in “Materials and Methods.”
Normalization to milligrams of creatinine was performed to account for variable urine concentrations.
Table 2 Buccal cell PA as measured with the Boc-Val-Pro-Arg-MCA substrate
Time after BBIC administration
6 h 24–48 h 2 wks 4 wks
No. of patients 7 10 10 12
Mean percentage increase from baseline 25% 15% 32% 19%
95% confidence interval 237% to 86% 236% to 66% 216% to 79% 228% to 66%
P 0.69 1.0 0.21 0.57
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clearly demonstrate reduced PA in normal cells exposed to
carcinogenic agents and subsequently treated with BBIC (17,
35, 39). We are currently examining PA in detail in a follow-up
Phase II clinical trial of BBIC (40, 41). We have demonstrated
interrelationships between neu protein levels and PA after
BBIC administration, providing insights on possible mecha-
nisms of BBI activity (40).
BBIC was found to be nontoxic when administered as a
single oral dose up to 800 CIU to human volunteers with oral
leukoplakia. p.o. administered BBI was absorbed and rapidly
excreted in the urine. Based on the lack of toxicity and the
demonstrated in vitro and animal model anticarcinogenic ef-
fects, we have recently completed a short-term (1-month) Phase
IIa study of BBIC and demonstrated a substantial clinical effect
against oral leukoplakia and effects on potential biomarkers. A
longer term (12-month) randomized Phase IIb study is planned.
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